Industry says that if cross country-coalitions on pricing and reimbursement are to succeed, the member countries need to be similar in terms of GDP and to guarantee pricing is kept confidential.
Cross-country coalitions aimed at securing lower prices and wider access to medicines are more likely to succeed in their mission if groups are comprised of countries with comparable economies and if they agree to keep pricing confidential, say industry groups. Resulting arrangements should also lead to accelerated and/or broader access to medicines, they say.
The comments come in response to recent news that Belgium and the Netherlands struck a pricing and reimbursement deal with...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
